Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial

Published

News published by Santhera Pharmaceuticals concerning Lonodelestat in cystic fibrosis, administered via an optimized eFlow® Technology nebulizer.
 

Read the press release

Back to overview